Lion Shutters iD3 Business; 86 Staffers in Heidelberg, San Diego Let Go | GenomeWeb

NEW YORK, Sept. 6 - Almost three months to the day after it said it wanted to sell off its iD3 drug-discovery business and focus more on core IT, Lion Bioscience has opted to shut down the unit altogether.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.